1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  09:09 2022-06-30 pm EDT
3460.00 JPY   -0.29%
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Supplementary Materials for Consolidated Financial Results for the 1st Quarter of Fiscal Year 2022. 12 (IFRS)

04/25/2022 | 04:19am EDT

Chugai Pharmaceutical co., ltd.

Notes: 1.

Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.

  • 2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.

  • 3. Exchange rates used for each period are as follows.

QTR

(Yen)

Actual*

Actual*

FY2021

FY2022

1-3

4-6

7-9

10-12

1-3

4-6

7-9

10-12

QTR

QTR

QTR

QTR

QTR

QTR

QTR

QTR

CHF

117.08

120.11

119.88

123.26

125.78

EUR

127.65

131.87

129.78

130.02

130.43

USD

105.83

109.44

110.08

113.66

116.17

SGD

79.47

82.12

81.39

83.75

85.92

*Market average exchange rate

YTD

Actual*

Actual*

Actual*

Assumption

FY2020

FY2021

FY2022

FY2022

1-12

1-3

1-6

1-9

1-12

1-3

1-6

1-9

1-12

1-12

Full-year

YTD

YTD

YTD

Full-year

YTD

YTD

YTD

Full-year

Full-year

CHF

113.72

117.08

118.60

119.03

120.10

125.78

122.00

EUR

121.69

127.65

129.76

129.77

129.83

130.43

130.00

USD

106.80

105.83

107.63

108.45

109.75

116.17

112.00

SGD

77.41

79.47

80.80

81.00

81.69

85.92

84.00

*Market average exchange rate

Period-end

Actual

Actual

Actual

FY2020

FY2021

FY2022

31 Dec.

31 Mar.

30 Jun.

30 Sep.

31 Dec.

31 Mar.

30 Jun.

30 Sep.

31 Dec.

CHF

117.10

117.14

120.02

119.76

125.95

131.93

EUR

126.89

129.30

131.48

129.85

130.31

135.92

USD

103.19

110.37

110.52

111.97

115.07

121.82

SGD

77.98

81.87

82.15

82.27

85.09

90.07

Reconciliation of IFRS results to Core results

(Billions of yen)

FY2021

FY2022

1-3

1-3

IFRS results

Intangible assets

Others

Core results

IFRS results

Intangible assets

Others

Core results

Revenues

168.8

-

-

168.8

360.6

-

(91.9)

268.6

Sales

130.3

-

-

130.3

242.7

-

-

242.7

Royalties and other operating income

38.6

-

-

38.6

25.9

-

-

25.9

Other revenue

-

-

-

-

91.9

-

(91.9)

-

Cost of sales

(55.3)

0.3

-

(55.0)

(114.4)

0.3

-

(114.1)

Gross profit

113.5

0.3

-

113.8

246.1

0.3

(91.9)

154.5

Ope

rating expenses

(49.5)

0.0

1.1

(48.5)

(59.1)

0.2

3.4

(55.6)

Marketing and distribution

(15.9)

-

0.0

(15.8)

(16.8)

-

0.1

(16.7)

Research and development

(29.7)

0.0

1.0

(28.7)

(33.9)

0.2

0.8

(32.9)

General and administration

(3.9)

-

0.0

(3.9)

(8.5)

-

2.5

(6.0)

Operating profit

64.0

0.3

1.1

65.4

187.0

0.4

(88.5)

98.9

Financing costs

(0.0)

-

-

(0.0)

(0.0)

-

-

(0.0)

Other financial income (expense)

0.3

-

-

0.3

1.6

-

-

1.6

Other expense

-

-

-

-

(2.4)

-

-

(2.4)

Pro

fit before taxes

64.2

0.3

1.1

65.6

186.2

0.4

(88.5)

98.1

Income taxes

(16.8)

(0.1)

(0.3)

(17.2)

(54.4)

(0.1)

27.0

(27.5)

Net income

47.4

0.2

0.8

48.4

131.8

0.3

(61.5)

70.6

Attributable to

Chugai shareholders

47.4

0.2

0.8

48.4

131.8

0.3

(61.5)

70.6

Non-controlling interests

-

-

-

-

-

-

-

-

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (0.3 billion yen in 2021 and 0.3billion yen in 2022)

Impairment (None in 2021 and 0.2billion in 2022)

Others

Income from settlement agreement (None in 2021 and -91.9billion yen in 2022) Restructuring expenses etc. (1.1 billion yen in 2021 and 3.4billion yen in 2022)

IFRS results (QTR)

3

4

5

6

(Billions of yen)

Actual

Actual

FY2021

FY2022

1-3

4-6

7-9

10-12

1-3

Change

(%)

4-6

Change

(%)

7-9

Change

(%)

10-12

Change

(%)

QTR

QTR

QTR

QTR

QTR

QTR

QTR

QTR

Revenues

168.8

221.4

287.3

322.3

360.6

+113.6

Sales

130.3

173.9

234.5

264.1

242.7

+86.3

Domestic

94.9

108.5

159.2

156.3

161.7

+70.4

Overseas

35.4

65.3

75.3

107.8

81.0

+128.8

Royalties and other operating income

38.6

47.5

52.7

58.1

25.9

(32.9)

Royalty and profit-sharing income

36.6

46.7

52.1

51.8

25.2

(31.1)

Other operating income

2.0

0.8

0.6

6.4

0.7

(65.0)

Other revenue

-

-

-

-

91.9

-

Cost of sales

(55.3)

(68.1)

(104.2)

(110.6)

(114.4)

+106.9

(% of Sales)

42.4

39.2

44.4

41.9

47.1

-

Gross profit

113.5

153.4

183.1

211.7

246.1

+116.8

(% of Revenues)

67.2

69.3

63.7

65.7

68.2

-

Operating expenses

(49.5)

(56.6)

(60.9)

(72.6)

(59.1)

+19.4

(% of Revenues)

29.3

25.6

21.2

22.5

16.4

-

Marketing and distribution

(15.9)

(17.9)

(18.5)

(24.3)

(16.8)

+5.7

(% of Revenues)

9.4

8.1

6.4

7.5

4.7

-

Research and development

(29.7)

(33.6)

(36.2)

(37.8)

(33.9)

+14.1

(% of Revenues)

17.6

15.2

12.6

11.7

9.4

-

General and administration

(3.9)

(5.2)

(6.3)

(10.5)

(8.5)

+117.9

(% of Revenues)

2.3

2.3

2.2

3.3

2.4

-

Operating profit

64.0

96.7

122.2

139.1

187.0

+192.2

(% of Revenues)

37.9

43.7

42.5

43.2

51.9

-

Financing costs

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

0.0

Other financial income (expense)

0.3

0.3

0.3

(0.9)

1.6

+433.3

Other expense

-

(0.0)

(2.8)

0.3

(2.4)

-

Profit before taxes

64.2

97.0

119.7

138.4

186.2

+190.0

(% of Revenues)

38.0

43.8

41.7

42.9

51.6

-

Income taxes

(16.8)

(26.3)

(33.7)

(39.6)

(54.4)

+223.8

Net income

47.4

70.7

86.0

98.8

131.8

+178.1

(% of Revenues)

28.1

31.9

29.9

30.7

36.6

-

Attributable to

Chugai shareholders

47.4

70.7

86.0

98.8

131.8

+178.1

Non-controlling interests

-

-

-

-

-

-

Earnings per share

Basic (yen)

28.84

43.02

52.31

60.11

80.14

+177.9

Diluted (yen)

28.82

42.99

52.28

60.08

80.09

+177.9

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

2

3

(Billions of yen)

Actual

Actual

Actual

FY2020

FY2021

FY2022

1-12

1-3

1-6

1-9

1-12

1-3

Change

(%)

1-6

Change

(%)

1-9

Change

(%)

1-12

Change

(%)

YTD

YTD

YTD

YTD

YTD

YTD

YTD

YTD

YTD

Revenues

786.9

168.8

390.2

677.5

999.8

360.6

+113.6

Sales

633.3

130.3

304.1

538.7

802.8

242.7

+86.3

Domestic

409.1

94.9

203.4

362.6

518.9

161.7

+70.4

Overseas

224.2

35.4

100.7

176.0

283.9

81.0

+128.8

Royalties and other operating income

153.6

38.6

86.1

138.8

196.9

25.9

(32.9)

Royalty and profit-sharing income

129.6

36.6

83.3

135.4

187.2

25.2

(31.1)

Other operating income

24.1

2.0

2.8

3.4

9.8

0.7

(65.0)

Other revenue

-

-

-

-

-

91.9

-

Cost of sales

(273.5)

(55.3)

(123.4)

(227.6)

(338.1)

(114.4)

+106.9

(% of Sales)

43.2

42.4

40.6

42.2

42.1

47.1

-

Gross profit

513.5

113.5

266.8

449.9

661.6

246.1

+116.8

(% of Revenues)

65.3

67.2

68.4

66.4

66.2

68.2

-

Operating expenses

(212.3)

(49.5)

(106.2)

(167.1)

(239.7)

(59.1)

+19.4

(% of Revenues)

27.0

29.3

27.2

24.7

24.0

16.4

-

Marketing and distribution

(72.6)

(15.9)

(33.8)

(52.2)

(76.6)

(16.8)

+5.7

(% of Revenues)

9.2

9.4

8.7

7.7

7.7

4.7

-

Research and development

(117.9)

(29.7)

(63.3)

(99.5)

(137.3)

(33.9)

+14.1

(% of Revenues)

15.0

17.6

16.2

14.7

13.7

9.4

-

General and administration

(21.8)

(3.9)

(9.1)

(15.3)

(25.8)

(8.5)

+117.9

(% of Revenues)

2.8

2.3

2.3

2.3

2.6

2.4

-

Operating profit

301.2

64.0

160.7

282.8

421.9

187.0

+192.2

(% of Revenues)

38.3

37.9

41.2

41.7

42.2

51.9

-

Financing costs

(0.1)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

0.0

Other financial income (expense)

(1.5)

0.3

0.6

0.9

0.1

1.6

+433.3

Other expense

(1.5)

-

(0.0)

(2.8)

(2.5)

(2.4)

-

Profit before taxes

298.2

64.2

161.3

280.9

419.4

186.2

+190.0

(% of Revenues)

37.9

38.0

41.3

41.5

41.9

51.6

-

Income taxes

(83.5)

(16.8)

(43.1)

(76.8)

(116.4)

(54.4)

+223.8

Net income

214.7

47.4

118.1

204.2

303.0

131.8

+178.1

(% of Revenues)

27.3

28.1

30.3

30.1

30.3

36.6

-

Attributable to

Chugai shareholders

214.7

47.4

118.1

204.2

303.0

131.8

+178.1

Non-controlling interests

-

-

-

-

-

-

-

Earnings per share

Basic (yen)

130.66

28.84

71.86

124.17

184.29

80.14

+177.9

Diluted (yen)

130.53

28.82

71.81

124.09

184.17

80.09

+177.9

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 25 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2022 08:18:04 UTC.


© Publicnow 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 186 B 8 725 M 8 725 M
Net income 2022 341 B 2 509 M 2 509 M
Net cash 2022 516 B 3 798 M 3 798 M
P/E ratio 2022 16,7x
Yield 2022 2,24%
Capitalization 5 706 B 41 992 M 41 992 M
EV / Sales 2022 4,38x
EV / Sales 2023 4,79x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 470,00 JPY
Average target price 4 577,69 JPY
Spread / Average Target 31,9%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-5.54%42 454
JOHNSON & JOHNSON3.43%465 732
ELI LILLY AND COMPANY16.94%290 752
PFIZER, INC.-14.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.84%272 382